Charlotte Thålin, adjunct professor at Karolinska Institutet’s Department of Clinical Sciences at Danderyd Hospital and senior consultant in internal medicine at Danderyd Hospital, will lead a research project, SCOPE, which aims to understand how protective antibodies in the airways can limit infections and inflammation in COPD.

Related article

Nasal organoids: Bridging the gap between lab and clinic

Growing two or three-dimensional human nasal tissue can lead to better reliability in research studies, personalized treatment strategies, and ultimately contribute to better outcomes for patients.


Through the project, Thålin and her team plan to recruit a large hospital-based cohort of COPD patients. The long-term goal is to develop an inhaled antibody therapy that can prevent respiratory infections and reduce disease progression.

According to the Swedish Heart-Lung Foundation, the study is highly advanced and holds significant potential. If successful, the approach could represent an important breakthrough for patients living with COPD.